Equities Research Analysts’ updated eps estimates for Monday, October 16th:

ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson’s disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. “

Atlas Financial Holdings (NASDAQ:AFH) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Atlas Financial Holdings Inc. provides commercial automobile insurance policies primarily in the United States through its subsidiaries. The company provides insurance coverage to taxi cabs, non-emergency para-transit, limousine/livery and business auto. Atlas Financial Holdings Inc. is based in United States. “

Aon PLC (NYSE:AON) had its buy rating reiterated by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $154.00 target price on the stock.

Appian Corporation (NASDAQ:APPN) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Appian Corporation provides low-code software development platform which enables organizations to develop various applications primarily in the United States and internationally. The Company’s products include business process management software, case management, mobile application development and platform as a service. It serves financial services, healthcare, government, telecommunications, media, energy, manufacturing and transportation organizations. Appian Corporation is headquartered in Reston, Virginia. “

Alibaba Group Holding Limited (NYSE:BABA) had its buy rating reaffirmed by analysts at Bank of America Corp. The firm currently has a $200.00 target price on the stock.

Brown & Brown (NYSE:BRO) had its hold rating reissued by analysts at Keefe, Bruyette & Woods. They currently have a $45.00 price target on the stock.

Cypress Energy Partners, L.P. (NYSE:CELP) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $9.00 price target on the stock. According to Zacks, “Cypress Energy Partners, L.P. offers saltwater disposal and other water and environmental services to U.S. onshore oil and natural gas producers and trucking companies primarily in North Dakota and west Texas. The Company operates in two segments: Water and Environmental Services and Pipeline Inspection and Integrity Services. It also provides independent pipeline inspection and integrity services to producers and pipeline companies. Cypress Energy Partners, L.P. is headquartered in Tulsa, Oklahoma. “

Cerus Corporation (NASDAQ:CERS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. “

CNX Coal Resources (NYSE:CNXC) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “CNX Coal Resources LP is engaged in production of thermal coal. It manages and develops CONSOL Energy’s active thermal coal operations primarily in Pennsylvania. The company sells its coal to electric utilities. CNX Coal Resources LP is based in CANONSBURG, United States. “

Connecture (NASDAQ:CNXR) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Connecture, Inc. provides web-based consumer shopping, enrollment and retention platform for health insurance distribution. It operates primarily in the United States. Connecture, Inc. is based in Brookfield, United States. “

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $24.00 target price on the stock. According to Zacks, “CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. “

DineEquity (NYSE:DIN) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “IHOP Corp. develops, franchises and operates International House of Pancakes restaurants. IHOP restaurants feature moderately-priced, high-quality food and beverage items, and table service in an attractive and comfortable atmosphere. Although IHOP restaurants are best known for their award-winning pancakes, omelets and other breakfast specialties, IHOP restaurants are open throughout the day and evening hours and offer a broad array of lunch, dinner and snack items as well. “

Delek US Holdings (NYSE:DK) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $30.00 price target on the stock. According to Zacks, “DELEK US HOLDINGS, INC. is a diversified energy business focused on petroleum refining, marketing and supply of refined products, and retail marketing of fuel and general merchandise. “

Equity Lifestyle Properties (NYSE:ELS) had its hold rating reissued by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $81.00 price target on the stock.

EQT Midstream Partners, (NYSE:EQM) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “EQT Midstream Partners, LP is formed to own, operate, acquire and develop midstream assets in the Appalachian Basin. The Company provides substantially all of its natural gas transmission, storage and gathering services under contracts with fixed reservation and/or usage fees. It operates primarily in the Marcellus Shale area of southern Pennsylvania and northern West Virginia. EQT Midstream Partners, LP is based in Pittsburgh, Pennsylvania. “

Fifth Street Finance Corp. (NASDAQ:FSC) had its hold rating reaffirmed by analysts at Keefe, Bruyette & Woods. They currently have a $6.00 price target on the stock.

Hutchison China MediTech Limited (NASDAQ:HCM) had its buy rating reaffirmed by analysts at Canaccord Genuity. The firm currently has a $38.00 target price on the stock.

Health Insurance Innovations (NASDAQ:HIIQ) had its buy rating reiterated by analysts at Canaccord Genuity. The firm currently has a $39.00 price target on the stock. The analysts wrote, “Date and time of first dissemination: October 16, 2017, 09:40 ET Date and time of production: October 16, 2017, 09:40 ET Target Price / Valuation Methodology: Health Insurance Innovations – HIIQ Our $39 PT is based on an 12.6x target multiple on our 2018 adj. EBITDA estimate. Our target multiple is a 25% discount to a peer group of non-provider health and insurance related technology companies.””

The Navigators Group (NASDAQ:NAVG) had its hold rating reiterated by analysts at Keefe, Bruyette & Woods. They currently have a $56.00 target price on the stock.

ServiceNow (NYSE:NOW) had its buy rating reiterated by analysts at Mizuho.

ProAssurance Corporation (NYSE:PRA) had its hold rating reaffirmed by analysts at Keefe, Bruyette & Woods. They currently have a $60.00 price target on the stock.

Primerica (NYSE:PRI) had its hold rating reissued by analysts at Keefe, Bruyette & Woods. The firm currently has a $87.00 price target on the stock.

Prudential Financial (NYSE:PRU) had its buy rating reiterated by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $121.00 target price on the stock.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its buy rating reissued by analysts at Canaccord Genuity. The analysts wrote, “Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible.””

RenaissanceRe Holdings (NYSE:RNR) had its hold rating reissued by analysts at Keefe, Bruyette & Woods. The firm currently has a $136.00 price target on the stock.

Summit Therapeutics PLC (NASDAQ:SMMT) had its buy rating reiterated by analysts at Canaccord Genuity.

THL Credit (NASDAQ:TCRD) had its hold rating reissued by analysts at Keefe, Bruyette & Woods. Keefe, Bruyette & Woods currently has a $10.50 price target on the stock.

Umpqua Holdings Corporation (NASDAQ:UMPQ) had its hold rating reissued by analysts at Keefe, Bruyette & Woods. They currently have a $20.00 price target on the stock.

Wells Fargo & (NYSE:WFC) had its buy rating reaffirmed by analysts at Keefe, Bruyette & Woods. They currently have a $59.00 target price on the stock.

Zealand Pharma A/S (NASDAQ:ZEAL) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $26.00 price target on the stock. The analysts wrote, “We recently hosted several meetings with investors and Zealand CEO Britt Jensen. Timelines appear intact for several events over the next 3-4 months, including results from a trial in healthy volunteers evaluating feasibility of once-weekly glepaglutide, presentation of Phase 2 glepaglutide data in Short Bowel Syndrome, initiation of a second Phase 3 dasiglucagon trial for Acute Hypoglycemia, and possibly initiation of a Phase 2/3 trial of dasiglucagon in a single-chamber pump format in Congenital Hyperinsulinism (CHI). Collectively, investors were interested in both glepaglutide and dasiglucagon programs, but individually, were more focused on one or the other. Reiterate BUY. We have not included pump applications of dasiglucagon in our valuation. Progress in the form of a deal with a pump maker and Phase 2/3 trial initiation in CHI would represent an important step forward for the company.””

Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.